Gemphire Therapeutics

General Information

We are a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both. We are developing our product candidate gemcabene (CI-1027), a novel, once-daily, oral therapy, for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy.

Employees: 8
Founded: 2008
Contact Information
Address 43334 Seven Mile Road, Suite 1000, Northville, MI 48167, US
Phone Number (248) 681-9815
Web Address
View Prospectus: Gemphire Therapeutics
Financial Information
Market Cap $110.2mil
Revenues $0.0 mil (last 12 months)
Net Income $-10.5 mil (last 12 months)
IPO Profile
Symbol GEMP
Exchange NASDAQ
Shares (millions): 3.0
Price range $10.00 - $10.00
Est. $ Volume $30.0 mil
Manager / Joint Managers Jefferies/ RBC Capital Markets
CO-Managers Canaccord Genuity/ Laidlaw & Company (UK)/ LifeSci Capital
Expected To Trade: 8/5/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change